Curanex Pharmaceuticals Inc
CURX
$0.32
-$0.01-3.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 240.41% | -- | |||
| Gross Profit | -240.41% | -- | |||
| SG&A Expenses | 187.08% | 374.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 225.09% | 1,548.70% | |||
| Operating Income | -225.09% | -1,548.70% | |||
| Income Before Tax | -222.09% | -1,482.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -222.09% | -1,482.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -222.09% | -1,482.26% | |||
| EBIT | -225.09% | -1,548.70% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -190.35% | -1,392.00% | |||
| Normalized Basic EPS | -190.56% | -1,356.25% | |||
| EPS Diluted | -190.35% | -1,392.00% | |||
| Normalized Diluted EPS | -190.56% | -1,356.25% | |||
| Average Basic Shares Outstanding | 10.83% | 6.67% | |||
| Average Diluted Shares Outstanding | 10.83% | 6.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||